 FRIENDSWOOD, Texas--BUSINESS WIRE--- CSTL DiffDxMelanoma--Castle Biosciences, Inc. Nasdaq: CSTL, a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced it has signed a definitive agreement to acquire all of the equity of Myriad myPath, LLC Myriad myPath Laboratory, from Myriad Genetics. Myriad myPath Laboratory is a CLIA-certified laboratory in Salt Lake City, where the myPath Melanoma 23-gene expression profile GEP test was develope 